ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2392

Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2494

Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-associated Vasculitis in Hong Kong : A Multi-centre Retrospective Cohort Study

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2381

Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2245

Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2050

Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2496

Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2027

Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2057

Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2115

Clinical Impact of Acute Symptomatic Vertebral Fractures in the United States: An Observational Study

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

10:30AM-12:30PM: Abstract Number: 2051

Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 1994

Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 2044

Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 1930

Clinical Significance of Positive ENA Testing in ANA-Negative Patients: A Retrospective Analysis of Rheumatologic Diagnoses

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2407

Clinical Utility of Repeat Renal Biopsies in Lupus Nephritis: The NIH Chronicity Index at First Biopsy Predicts Future End Stage Renal Disease in a Large South Asian Cohort of SLE

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2208

Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry

RA – Diagnosis, Manifestations, & Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].